// App-Quantinova.ai

: Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Researchers

Presenter

  • Partow Kebriaei

Principal Investigators

  • Daniel J. DeAngelo

  • Anjali S. Advani

  • Susan M. O'Brien

  • David Marks

  • Hagop M. Kantarjian

  • Elias J. Jabbour

  • Tao Wang

  • Erik Vandendries

  • A. Douglas Laird

  • Sonja Nick

  • Matthias Stelljes

Medical Centers

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH

  • University of California Irvine Medical Center, Orange, CA

  • University of Bristol, Bristol, United Kingdom

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX

  • Pfizer, Groton, CT

  • Pfizer Inc., Cambridge, MA

  • Pfizer Inc, San Diego, CA

  • Pfizer AG, Zürich, Switzerland

  • Universitatsklinikum Munster, Munster, Germany

Locations

  • United States

  • United Kingdom

  • Switzerland

  • Germany

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

  • Mitoxantrone

  • fludarabine tablet

  • Cytarabine liposomal

  • ara-c

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01564784

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved